Effect of zoledronic acid on the vertebral body bone mineral density after instrumented intervertebral fusion in postmenopausal women with osteoporosis

This study evaluated the effect of anti-osteoporosis treatment with intravenous zoledronic acid during the perioperative period, on the adjacent vertebral body bone mineral density (BMD) after spinal fusion surgery in postmenopausal women with osteoporosis. All data were collected retrospectively from patients' medical records using standardized forms, including: demographics (age, BMI, years since menopause); surgical details of levels included (fusion level and cephalad levels); and BMD values. BMD values (g/cm2) were recorded for the overall lumbar spine, for the levels cephalad to the fused segments, and the femoral neck. The group 0 represents the treated group and group 1 represents the untreated group. The table 1 shows the data about the description of demographic and surgery information of treated group and untreated group. Additionally, the table 2 shows the information about cephalad adjacent vertebral and femoral neck BMD value change. The conclusion shows that perioperative zoledronic acid treatment may offer protection against a significant decrease in BMD of cephalad vertebrae after spinal fusion surgery among postmenopausal women with osteoporosis.本研究针对绝经后骨质疏松症女性，评估了脊柱融合术围手术期静脉注射唑来膦酸行抗骨质疏松治疗对术后相邻椎体骨密度（Bone Mineral Density, BMD）的影响。所有数据均通过标准化采集表从患者病历中回顾性提取，涵盖人口统计学信息（年龄、体质量指数（Body Mass Index, BMI）、绝经年限）、手术相关细节（融合节段及头侧节段）以及骨密度值。骨密度值（单位：g/cm²）分别记录了全腰椎、融合节段头侧节段以及股骨颈的检测结果。0组为治疗组，1组为未治疗组。表1展示了治疗组与未治疗组的人口统计学及手术信息概况。此外，表2呈现了头侧相邻椎体与股骨颈骨密度的变化情况。研究结论表明，围手术期唑来膦酸治疗可对绝经后骨质疏松症女性脊柱融合术后头侧椎体骨密度的显著降低起到保护作用。